In recent years, further understanding of the interaction between the immune system and tumor growth has led to the development of several immunotherapies. These immunotherapies include cancer vaccines and immune checkpoint inhibitors that have been tested in various solid tumors, including those traditionally considered non-immunogenic, such as non-small cell lung cancer (NSCLC). In physiological state, T-cell-mediated immune response against foreign antigens is regulated by stimulatory and inhibitory signals, which are critical to prevent autoimmunity and protect normal tissues after immune system activation. Cancer cells harbor different genetic and epigenetic alterations; thus, neoantigens that are potentially recognized and eliminated by the immune system are expressed. Adaptive immune responses, particularly IFN-γ-secreting T cells, exert a core function in tumor immune surveillance. However, tumors can escape this surveillance and maintain an immunosuppressive microenvironment through multiple mechanisms, including recruitment of regulatory cells (e.g., regulatory T cells, myeloidderived suppression cells, and type 2 macrophages) and production of molecules suppressing antitumor T-cell responses (e.g., interleukin-10 and transforming growth factor-β). Tumor growth is also associated with immunomodulation of T-cell response through enhancement of co-inhibitory molecules or immune checkpoints, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or programmed cell death-1 (PD-1), on T cells 1, 2 . Immunotherapies may affect various tumors by activating adaptive immune system response, including blockade of immune checkpoint pathways.
PD-1 receptor is highly expressed by activated T cells, B cells, and natural killer cells 3 . The well-known ligands of PD-1 are PD-L1 (or B7-H1) and PD-L2 (or B7-DC). PD-L1 is expressed in macrophages and can be induced by inflammatory cytokines on tumors, immune cells, and various tissues (Figure 1) . After ligand binding, PD-1 inhibits kinase signaling pathways involved in T-cell activation; thus, this process prevents overstimulation of immune response. PD-L1 also binds CD80 receptor, which is another negative regulator of T-lymphocyte activation. PD-1 primarily inhibits T-cell activity in the effector phase within tissues and tumors, whereas CTLA-4 regulates immune responses early in T-cell activation. this committee concluded that the study reached its endpoint, demonstrating superior overall survival with nivolumab compared with docetaxel in patients with advanced squamous NSCLC pretreated with platinum-based chemotherapy. The abovementioned trials included patients regardless of their PD-L1 status. First-line treatment with nivolumab conferred a significant improvement in overall survival and progression-free survival compared with dacarbazine, with low risk of high-grade toxic effects, in a phase III randomized trial including patients with metastatic melanoma without BRAF mutation 7 . In the current study, secondary endpoints included correlation of tumor PD-L1 expression with overall survival. Nivolumab provides significant clinical benefits in different cancer types; thus, identification of predictive response factors is crucial to select patients who will most likely benefit from treatment, while sparing resistant patients from unnecessary toxicity. PD-1/PD-L1 is predominantly involved in the final stages of immune response between T cells and tumors; therefore, most biomarker investigations have focused on tumor microenvironment. Specifically, several studies have explored PD-L1 expression in tumor cells from patients treated with PD-1/PD-L1 axis inhibitors, and significant antitumor activity has been shown in patients with PD-L1-positive tumors, although responses have also been observed in PD-L1-negative patients [5] [6] [7] [8] [9] [10] .
To clearly observe the complexity of mechanisms involved in tumor response to PD-1 blockade among different tumor types, Taube renal-cell carcinoma, colorectal carcinoma, and castration-resistant prostate cancer (CRPC) were analyzed. PD-L1 expression varied among tumors and mainly occurred in tumor cells of melanoma, NSCLC, and kidney cancer specimens, in contrast to only one colorectal and no CRPC specimens. Tumor PD-L1 expression was significantly correlated with infiltrating immune cells, including lymphocytes and histiocytes (P=0.001), and the proportion of PD-L1-positive tumor cells correlated with infiltrate intensity (P=0.003). PD-L1 expression was also observed in TILs and histiocyte/macrophages among different tumor types, including some colorectal cancer specimens, in which tumoral PD-L1 expression was very low. Interestingly, the receptor PD-1 expression in TILs was significantly associated with the expression of its ligand, PD-L1, in tumor cells and immune cell infiltrates; this finding suggested the presence of a potentially immunosuppressive environment. Furthermore, PD-L2 function in immunosuppression mediation was explored in the present study. PD-L2 was less expressed than PD-L1, but its interaction with PD-1 was also blocked by nivolumab. Only 8 (21%) out of 38 specimens showed PD-L2 expression in tumor or infiltrating immune cells, which were mainly associated with PD-L1 expression.
To assess the predictive function of pathological features in patients with multiple specimens (16/41, 39%), an analysis was conducted by considering only the specimen closest to nivolumab initiation or that with maximum expression of each variable. Tumor PD-L1 expression was significantly associated with objective response (P=0.025), as assessed by RECIST 1.0, and clinical benefit (objective response or stable disease ≥6 months; P=0.005). PD-L1 expression by immune cells was significantly correlated with clinical benefit only. Considering the presence of TILs correlated with tumor cell PD-L1 expression, such marker was analyzed as an independent potential predictive factor, although this marker was not correlated with favorable clinical outcomes to nivolumab. All other microenvironment factors were analyzed, including PD-1 and PD-L2 expression; CD4:CD8 ratio, CD20 + B cells, and tumor necrosis of lymphoid aggregates were not correlated with response to treatment. Correlation of PD-L1 expression with clinical outcome was not related to the timing of tissue acquisition (ranging from 0 to 13 years). Taube suggested that PD-L1 expression does not exclusively represent an immunosuppressive factor; such marker may mainly reflect an ongoing antitumor immune response characterized by an immune-activated microenvironment and the production of various cytokines and inflammatory factors (e.g., IFN-γ) that induce PD-L1 and PD-L2 expression. PD-L2 was correlated with PD-L1 expression, but pure PD-L2 showed no correlation with response to nivolumab or other PD1/PD-L1 agents 10, 11 . Importantly, PD-L1 expression patterns and characteristics of immune infiltrates can vary among tumor types, and these factors can affect response to PD-1 blockade. Majority of melanoma, kidney cancer, and NSCLC showed PD-L1 expression in tumor cells, which were also correlated with immune infiltrate intensity in melanoma and kidney cancers. By contrast, PD-L1 expression occurred in infiltrating immune cells; however, this process was absent in tumor cells among colorectal cancers. As underlined by the authors, these distinct expression patterns may reflect heterogeneity of immune response among various tumors, which can be influenced by specific genetic changes within the tumor and by other tumor stromal components. Tumor cells express various neoantigens, including those associated with somatic mutations or infection by tumor-promoting viruses, which can activate a local inflammatory response that is potentially responsible for PD-L1 up-regulation. In some cancer types, PD-L1 expression has been associated with activation of downstream signals, including PI3K/AKT, PTEN, and ALK/STAT3 pathways; therefore, this process may target immune response in some oncogene-addicted tumors [11] [12] [13] [14] . PD-L1 expression has also been demonstrated to be either a negative or positive prognostic biomarker in different tumor types [15] [16] [17] [18] . The presence of TILs, which have been correlated with chemotherapy or immunotherapy activity in some advanced cancers, may be necessary to drive PD-L1 expression in tumors. However, in the present study, TILs were not independently correlated with response. This study also reported the association of PD-L1 expression by infiltrating immune cells with clinical benefits from nivolumab, although tumor PD-L1 expression was the most important factor associated with objective response. In a recent study on patients with different cancer types treated with anti-PD-L1 monoclonal antibody, MPDL3280A, the association of PD-L1 expression by infiltrating immune cells in pretreatment samples with objective response was stronger than that with tumor cell PD-L1 expression; therefore, these cells may be involved in a pre-existing T-cell activity suppression by PD-L1 before therapy. This pre-existing immunity can serve a crucial function in determining response to treatment with MPDL3280A 10 . Different studies significantly reported that some rates of objective response to PD-1 pathway blockade have been observed in patients with PD-L1-negative tumors; thus, PD-L1 expression may not be the only predictive factor for this class of inhibitors [5] [6] [7] [8] [9] [10] . The survival benefit from first-line nivolumab versus dacarbazine was observed across all prespecified subgroups of metastatic melanoma patients, including subgroups defined by PD-L1 status 7 . Results in terms of PD-L1 expression predictivity are difficult to interpret because studies significantly vary with regard to the use of different antibodies for IHC analysis, different cutoff levels used to define positivity, and different methods of sample collection, processing, and storage. In some nivolumab studies, PD-L1 expression was evaluated using anti-PD-L1 monoclonal antibody 5H1 (threshold for positivity: 5% expression per specimen), whereas others used an automated IHC assay based on a sensitive and specific anti-PD-L1 monoclonal antibody, 28-8 (positivity: ≥5% tumor cells showing membrane staining of any intensity in a section containing at least 100 tumor cells). Sample size can also affect the results because of the focal nature of PD-L1 expression in tumors and known intratumoral genetic heterogeneity. Furthermore, given the dynamic nature of antitumor response, site (anatomical location), and time of collection (primary or metastatic cancer), biopsy can affect the expression of PD-L1 and other immunologic factors. However, in the trial conducted by Taube et al.
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, no significant correlations existed between biopsy characteristics and PD-L1 expression. In some studies, result interpretation was also limited by the small number of patients analyzed. Overall, these data suggest that patients with PD-L1-negative tumors should not be considered ineligible for these highly effective immunotherapeutic approaches. The predictive function of PD-L1 expression and other immunoarchitectural features of pretreatment tumors will be specifically addressed in ongoing phase II and III trials on PD-1/PD-L1 pathway inhibitors in different solid tumors, including melanoma and NSCLC. Additional studies on tumor microenvironment factors and their relationship with PD-L1 expression are needed to better elucidate the different clinical activities of immunotherapies across tumor types. In melanoma, other immunological events seem to affect response to treatment, such as pre-existing CD8 + T cell infiltration at the invasive tumor margin, which is associated with the expression of PD-1 and PD-L1 immune inhibitory axis and correlated with response to pembrolizumab 19 . Furthermore, in melanoma, pretreatment tumors in responding patients demonstrated elevated IFN and IFN-inducible gene expression (e.g., CXCL9); these associations were not found in NSCLC or renal cancer 10 . Recent studies have demonstrated that genomic tumor landscape can predict response to immune checkpoint inhibitors. Some tumors, including NSCLC and melanoma, are characterized by very high mutational burdens. Neoantigens created within these tumors can trigger and construct immune responses that can be enhanced by immunologic checkpoint blockade. NSCLC specimens from patients treated with the anti-PD-1 pembrolizumab were characterized by whole-exome sequencing; a higher mutational load was also strongly associated with clinical efficacy 20 . Moreover, efficacy is correlated with a molecular smoking marker, specific DNA repair pathway mutations, and higher burden of candidate neoantigens. Similarly, in melanoma patients treated with ipilimumab, a long-term clinical benefit was associated with high mutational load 21 . However, some tumors with high load of somatic mutations failed to respond to checkpoint blockade; therefore, other tumor characteristics may affect therapeutic benefit. In the same study, researchers identified a set of neoantigens that were common to patients who presented a sustained clinical benefit; however, these neoantigens were completely absent in patients with minimal or no benefit. This specific marker in tumors can be potentially useful to select patients who will most likely benefit from CTLA-4 blockade. Our knowledge about the mechanisms involved in the interactions between the immune system and tumors is rapidly evolving. In this context, the work of Taube et al. provided a crucial contribution to elucidate how these mechanisms can be exploited to predict response to anti-PD-1 therapy and facilitate further investigations in this field.
